Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 19/20 | 0.86 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.69 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.69 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3759110 | 1.00 | PDE4A (0.86) | PDE4APDE4DPDE4BPDE4C | |
| SCHEMBL7430085 | 0.97 | PDE4A (0.82) | PDE4APDE4DPDE4BPDE4C | |
| SCHEMBL29370366 | 0.93 | PDE4A (1.00) | PDE4APDE4DPDE4BPDE4C | |
| SCHEMBL7907449 | 0.90 | PDE4A (0.85) | PDE4APDE4DPDE4BPDE4C | |
| SCHEMBL6755456 | 0.89 | PDE4A (0.83) | PDE4APDE4DPDE4BPDE4C | |
| SCHEMBL8690001 | 0.89 | PDE4A (0.77) | PDE4APDE4DPDE4BPDE4C | |
| SCHEMBL7531755 | 0.89 | PDE4A (0.77) | PDE4APDE4DPDE4BPDE4C | |
| Hydrochloric Acid SCHEMBL7412911 | 0.88 | PDE4A (0.71) | PDE4APDE4DPDE4BPDE4C | |
| Hydrochloric Acid SCHEMBL7412907 | 0.88 | PDE4A (0.71) | PDE4APDE4DPDE4BPDE4C | |
| SCHEMBL6754527 | 0.88 | PDE4A (0.79) | PDE4APDE4DPDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0626939-B1 | TRI-SUBSTITUTED PHENYL DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | CELLTECH THERAPEUTICS LTD (GB) | 2001-11-07 | — | — | EP | claimed |
| US-20130225597-A1 | USE OF PHOSPHODIESTERASE INHIBITOR TO ENHANCE POST-SURGICAL ERECTION IN MEN UNDERGOING RADICAL PROSTATECTOMY | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2013-08-29 | — | — | US | disclosed |
| US-20120184517-A1 | TREATMENT OF DISEASES WITH ALTERED SMOOTH MUSCLE CONTRACTILITY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-07-19 | — | — | US | disclosed |
| WO-2010126609-A2 | TREATMENT OF DISEASES WITH ALTERED SMOOTH MUSCLE CONTRACTILITY | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2010-11-04 | — | — | WO | disclosed |
| US-20040209916-A1 | Combination therapies | PFIZER INC | 2004-10-21 | — | — | US | disclosed |
| US-20040087653-A1 | Methods for the treatment of respiratory diseases and conditions with a selective iNOS inhibitor and a PDE inhibitor and compositions therefor | MANNING PAMELA T (US) | 2004-05-06 | — | — | US | disclosed |
| US-20030022814-A1 | Method for treating or preventing depression | REINES SCOTT A (US) | 2003-01-30 | — | — | US | disclosed |
| US-20010049368-A1 | Method for treating or preventing depression | REINES SCOTT A (US) | 2001-12-06 | — | — | US | disclosed |
| EP-0626939-B1 | TRI-SUBSTITUTED PHENYL DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | CELLTECH THERAPEUTICS LTD (GB) | 2001-11-07 | — | — | EP | disclosed |
| WO-2001064223-A1 | METHOD FOR TREATING OR PREVENTING DEPRESSION | MERCK FROSST CANADA & CO. (CA) | 2001-09-07 | — | — | WO | disclosed |
| US-5622977-A | ANTIINFLAMMATORY AGENT, ANTIALLERGENS | CELLTECH THERAPEUTICS LIMITED (GB) | 1997-04-22 | — | — | US | disclosed |
| EP-0626939-A1 | TRI-SUBSTITUTED PHENYL DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | CELLTECH THERAPEUTICS LIMITED (GB) | 1994-12-07 | — | — | EP | disclosed |
| WO-1994014742-A1 | TRI-SUBSTITUTED PHENYL DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | CELLTECH LIMITED (GB) | 1994-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087653-A1 | Methods for the treatment of respiratory diseases and conditions with a selective iNOS inhibitor and a PDE inhibitor and compositions therefor | NOS2, NOS1, PDE3A | PDE4A 14/4885PDE4D 45/4885PDE4B 13/4885 |
| US-20040209916-A1 | Combination therapies | ADRA2C, ADRB2, ADRA2A | PDE4A 17/4885PDE4D 25/4885PDE4B 18/4885 |
| US-20120184517-A1 | TREATMENT OF DISEASES WITH ALTERED SMOOTH MUSCLE CONTRACTILITY | MYLK, MYLK2, MYH10 | PDE4A 31/4885PDE4D 88/4885PDE4B 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.